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OBJECTIVE—We aimed to investigate the inﬂuence of positive family history (FH+) of di-
abetesand19knowngeneticrisklociontheeffectivenessoflifestylechangesandtheirpredictive
value on the incidence of type 2 diabetes in the Finnish Diabetes Prevention Study (DPS).
RESEARCH DESIGN AND METHODS—A total of 522 subjects with impaired glucose
tolerance (IGT) were randomized into the control (n = 257) and intervention (n = 265) groups.
The mean follow-up was 6.2 years (median 7 years), and the lifestyle intervention, aimed at
weight reduction, healthy diet, and increased physical activity, lasted for 4 years (range 1–6
years). An oral glucose tolerance test (OGTT) and assessment of basic clinical variables were
performed annually.
RESULTS—The effect of intervention on the incidence of diabetes was almost similar in sub-
jects with FH+ compared with subjects with a negative family history (FH2) of diabetes during
the entire follow-up. In the Cox model, including FH, genetic risk SNPs, and randomization
group, and adjusted for the effects of age, sex, BMI, and study center, only lifestyle intervention
had a signiﬁcant effect (hazard ratio 0.55, 95% CI 0.41–0.75, P , 0.001) on the incidence of
diabetes. Further analyses showed that in addition to the baseline glucose and insulin values,
1-year changes in 2-h glucose and 2-h insulin achieved by lifestyle intervention had a signiﬁcant
effect on the incidence of diabetes.
CONCLUSIONS—These results emphasize the effectiveness of lifestyle intervention in re-
ducing the risk of diabetes in high-risk individuals independently of genetic or familial risk of
type 2 diabetes.
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B
oth genetic and environmental fac-
tors play major roles in the develop-
ment of type 2 diabetes mellitus. In
recent years, the research aiming to ex-
plore the genetic basis of type 2 diabetes
has progressed signiﬁcantly. Currently,
.30 genetic variants have been identiﬁed
in large multicenter studies with sufﬁ-
cient power to be associated with an in-
creased risk of type 2 diabetes (1–3).
Typically, each variant has only a limited
effect on the risk, i.e., the risk may in-
crease by 10 to 15% per copy of each
risk allele except for TCF7L2, which is so
far the most convincing type 2 diabetes
risk gene, increasing the risk 1.4-fold
(2). The known risk variants explain
only ;10% of the genetic basis of type 2
diabetes (2). On the basis of ﬁndings in a
limited number of longitudinal studies,
the risk variants have only a small effect
on the ability to predict the development
of type 2 diabetes (4–6). In two lifestyle-
baseddiabetespreventiontrialsinpersons
with impaired glucose tolerance (IGT),
the Diabetes Prevention Program (DPP)
and the Finnish Diabetes Prevention
Study(DPS),ithasbeenpossibletoexam-
ine the interaction between genetic and
lifestyle factors regarding the future risk
of diabetes. In these studies, lifestyle
changes modiﬁed the risk of diabetes de-
pending on the genetic variation (2,7,8).
Speciﬁcally, the increased risk of type 2
diabetes was completely abolished by
lifestyles in both DPP and DPS among
the persons with the risk allele for
TCF7L2 (9,10). It is commonly believed
that type 2 diabetes is highly heritable
(11), and a positive family history (FH+)
predicts the development of type 2 diabe-
tesevenafteradjustmentforcommonrisk
factorsfortype2diabetes(4–6,12–14).In
the DPP, the known genetic risk variants
were not associated with an increased
risk of diabetes, and only one potential
genotype-intervention interaction for
CDKN2A/B was reported previously
(15). However, the responses to lifestyle
according to FH of diabetes were not
documented.
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Pathophysiology/Complications
ORIGINAL ARTICLEThe aim of the current study was
to investigate whether an FH+ of diabetes
or genetic variants of type 2 diabetes could
modulate the effect of lifestyle changes
achieved in the Finnish DPS (16,17) on
the incidence of type 2 diabetes. Further-
more, we aimed to assess the ability of FH
andgeneticriskvariants,inadditiontolife-
stylechangesandbasicclinicalvariables,to
predict the incidence of type 2 diabetes in
individuals at high risk of type 2 diabetes.
RESEARCH DESIGN AND
METHODS—T h eD P Si sac l i n i c a lt r i a l
with ﬁve participating centers (Helsinki,
K u o p i o ,T u r k u ,T a m p e r e ,a n dO u l u )i n
Finland (NCT00518167). Details of the
DPS study design, methods, and proce-
dures have been published (16–19).
Brieﬂy, study participants were recruited
mainly by screening of high-risk groups
who voluntarily responded to local adver-
tisements. The inclusion criteria were 1)
age 40–64 years at screening, 2) BMI
.25 kg/m
2 at screening, and 3) the
mean value of two 75-g oral glucose toler-
ance tests (OGTTs) in the IGT range
based on World Health Organization
1985 criteria. Exclusion criteria included
recent (within 6 months) cardiovascular
disease event. The randomization of par-
ticipants started in 1993 and continued
until 1998.
A total of 522 overweight men and
womenwererandomlyallocatedtooneof
the two treatment modalities, the inten-
sive diet-exercise counseling group (n =
265, 66% were women) or the control
group (n = 257, 69% were women). The
participants randomized to intensive life-
style intervention were given individual-
ized counseling by the study nutritionists
to achieve the lifestyle goals. They were
also advised to increase their level of
physical activity, and voluntary physical
activity sessions were offered. The life-
style goals were 1) weight reduction of
$5%, 2) ,30% of the daily energy intake
from fat, 3) ,10% of the daily energy in-
take from saturated fat, 4) ﬁber intake
$15 g per 1,000 kcal, and 5) moderately
intense physical activity $30 min per
day. The control participants were given
general health behavior information at
randomization. The median length of
the active intervention period was 4 years
(range 126y e a r s ) .
All participants had an annual
OGTT, a medical history, and a physical
examination with measurements of
height (without shoes), weight (in light
indoor clothes), waist circumference
(midway between the lowest rib and iliac
crest), and systolic and diastolic blood
pressure. Serum total cholesterol, HDL
cholesterol, and triglycerides were deter-
mined from fasting samples using an
enzymatic assay method.
The diagnosis of diabetes was based
on the repeated OGTT (16,17). FH of di-
abetes was based on a questionnaire ap-
p l i e di nt h eD P S .I fo n eo ft h eﬁrst-degree
relatives (father, mother, sister, brother)
had diabetes, FH was regarded as positive
(FH+). These data are based on the follow-
up of 4 years when active intervention was
ﬁnished and on the 3 years of follow-up
after active intervention with a total follow-
up of an average of 6.2 years (median
7 years). Altogether, 75 persons (28%) in
the intervention group and 110 persons
(43%) in the control group developed di-
abetes during the entire follow-up. During
the entire study period, the incidence of
diabetes was substantially lower in the in-
tervention group compared with the con-
trol group (HR 0.57, 95% CI 0.4320.76,
P , 0.001) (18). No signiﬁcant difference
was found in mortality rates between the
groups (19).
Genotyping
Nineteen type 2 diabetes-susceptibility
SNPs (PPARG rs1801282, KCNJ11
rs5219, TCF7L2 rs7903146, SLC30A8
rs13266634,HHEX rs1111875,CDKN2B
rs10811661, IGF2BP2 rs4402960,
CDKAL1 rs7754840, FTO rs9939609,
HNF1B rs757210, WFS1 rs10010131,
JAZF1 rs864745, CDC123 rs12779790,
TSPAN8 rs7961581, THADA rs7578597,
ADAMTS9 rs4607103, NOTCH2
rs10923931,KCNQ1rs2283228,MTNR1B
rs10830963) were genotyped using the
TaqMan Allelic Discrimination Assay (Ap-
plied Biosystems, Foster City, CA). The
genotyping call rate was 99.22100%. Ge-
notype distributions of all SNPs were in
Hardy–Weinberg equilibrium (P . 0.05).
Calculations
Genetic risk score (GRS) for type 2 di-
abetes was calculated as a sum of type 2
diabetes-risk alleles in 19 conﬁrmed type
2 diabetes-susceptibility SNPs. Further-
more,GRSSECRbasedoneightSNPsinﬂu-
encing insulin secretion (at loci KCNJ11,
TCF7L2, SLC30A8, HHEX, CDKN2B,
IGF2BP2, CDKAL1, MTNR1B) (20) was
calculated.
Statistical analysis
Baseline differences in characteristics of
the FH+ group and the group with a
negative family history (FH2) of diabetes
were tested with the t test for continuous
variablesandtheFisherexactorx
2testfor
dichotomous variables. Changes during
follow-up (D values between the value at
1yearoffollow-upandthebaselinevalue)
in body weight, glucose, and other vari-
ables were analyzed with the general linear
model,adjustingforage,sex,studycenter,
BMI,andfastingglucoseatbaseline.Inter-
actionbetweenFHandtherandomization
groupwastestedforeachmodel,modeled
as ﬁxed factor. Variables with non-normal
distribution were log-transformed before
analyses. Kaplan–Meier method was used
toestimatetheincidenceofdiabetesinthe
two groups. The difference in incidence
between the groups was tested with the
log-rank test. The Cox proportional haz-
ards model was used to estimate the haz-
ard ratio for the development of diabetes
betweenthegroups.Hazardratiosforcon-
tinuous traits areexpressedasunit change
per 1 SD. If not stated otherwise, the
models were adjusted for age, sex, BMI at
baseline, fasting glucose at baseline, and
study center. No multicollinearity prob-
lemswerefoundforanymodel.Interaction
between FH (or GRS) and randomization
group was modeled as a covariate in Cox
regression. All comparisons of the end
points were based on the intention-to-
treat principle. The results for continuous
variables are given as means 6 SD. P ,
0.05 was considered statistically signiﬁ-
cant.Analysesweredonewith the statistics
package Stata version 10.1 (StataCorp.,
College Station, TX) and SPSS 14.0 (SPSS
Inc., Chicago, IL).
RESULTS
Baseline characteristics and 1-year
changes in clinical variables by
family history
Nosigniﬁcantdifferenceintheprevalence
of FH of diabetes was observed between
theinterventionandcontrolgroups(66%
vs. 61%). Table 1 shows baseline charac-
teristics of the DPS participants according
to the FH of diabetes. With the exception
ofthe 1-yeardifferenceinage (P=0.012),
the two groups (FH+ vs. FH2) did not
differ signiﬁcantly from each other. Fur-
thermore, persons with FH+ and FH2
weresimilarregardingtheirdietatbaseline,
but the total leisure time physical activity
was greater in persons with FH2.
The 1-year changes in the main clin-
ical and metabolic characteristics accord-
ing to FH and randomization group
(intervention vs. control group) are
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Uusitupa and Associatesshown in Supplementary Table 1. As
shown previously, weight reduction was
greater and glycemic control improved
more in the intervention group than in
the control group (17,18). In the inter-
vention group, persons with FH+ ach-
ieved signiﬁcantly greater reduction in
2-h plasma glucose than did persons
with FH2.H o w e v e r ,n os i g n i ﬁcant in-
teractions between FH and control/
intervention groups were found in the
changes in body weight, fasting plasma
glucose, 2-h plasma glucose, homeosta-
sismodelassessment(HOMA)ofinsulin
resistance, HOMA of insulin sensitivity,
or energy intake. In addition, no major
differences were found in the distribution
of macronutrients or physical activity be-
tween FH+ and FH2 groups after 1 year
of intervention (data not shown).
Incidence of type 2 diabetes by
family history
Incidence of type 2 diabetes in the in-
tervention and control group by FH of
diabetes is shown in Fig. 1 (data in
Supplementary Table 2). During the orig-
inal randomized trial period of 4 years on
average, the incidence of diabetes seemed
tobelowerintheinterventiongroupthan
in the control group in persons with FH+
(P = 0.0002), but not in those with FH2
(P = 0.61). After adjustment for age, sex,
baseline BMI, fasting glucose, and study
center, the HR for diabetes in the inter-
vention group compared with the control
group was 0.42 (95% CI 0.2620.70, P =
0.0008) in persons with FH+, whereas it
was 0.61 (95% CI 0.3321.12, P = 0.11)
in persons with FH2. During the entire
follow-up, in the adjusted model, the
effect of intervention was, however, sig-
niﬁcantinbothFH+(P=0.002)andFH2
(P = 0.006) groups, and there was no
signiﬁcant interaction between the FH
and randomization group (P =0 . 1 9f o r
the follow-up during intervention, P =
0.97 for the entire follow-up).
Effect of gene variants and genetic
risk score on the incidence of
type 2 diabetes
We did not ﬁnd any signiﬁcant effects of
the 19 risk variants on the incidence of
type 2 diabetes (data not shown). Simi-
larly,combinedtype2diabetesriskalleles
of 19 SNPs (presented as GRS) did not
h a v eas i g n i ﬁcant effect on the incidence
of diabetes during the entire follow-up
period (P = 0.784 in the adjusted model).
GRS based on eight SNPs inﬂuencing in-
sulin secretion (20) (GRSSECR) also did
not have a signiﬁcant effect (P = 0.459).
The persons with FH+ and FH2 did not
differ in the GRS (17.5 6 2.7 vs. 17.6 6
2.8,P =0.726).Nostatisticalevidence for
an interaction between GRS (or GRSSECR)
and randomization group on the inci-
dence of type 2 diabetes was found (P =
0.656 or 0.340 for the interaction).
Predictors of the incidence of type 2
diabetes
In the Cox regression analysis, including
GRS (19 SNPs), FH, and randomization
group, adjusted for age, BMI, sex, and
center, only the intervention group had a
signiﬁcant effect on the incidence of di-
abetes (Table 2). A further Cox regression
analysis including age, sex, BMI, fasting
and 2-h glucose and fasting and 2-h in-
sulin at baseline, GRS (as a continuous
variable), FH, randomization group, and
study center in the model was performed
to determine the predictors of the inci-
dence of type 2 diabetes during the entire
follow-upperiod(Table2).Itshowedthat
fastingand2-hplasmaglucose,fastingin-
sulin, and the randomization group sig-
niﬁcantly predicted the development of
diabetes. Fasting glucose was the stron-
gest predictor (P =2 . 23 10
210). This
could be explained by the inclusion crite-
ria of the study, comprising only subjects
with IGT. However, when the 1-year
changes of metabolic variables were
added in the model baseline, fasting and
2-h glucose, baseline fasting insulin, and
changes in 2-h glucose and insulin pre-
dicted the incidence of diabetes (Table 2).
N e i t h e rF Hn o rG R Sw a sas i g n i ﬁcant
predictor of the development of type 2
diabetes, and the effect of the intervention
became nonsigniﬁcant (HR 0.74, P =
0.106) because the effect of lifestyles
surely was mediated through glucose
and insulin metabolism.
CONCLUSIONS—The current study
aimed to investigate whether the FH+ per
se, or the genetic risk variants and GRS
based on 19 known type 2 diabetes-risk
SNPs, modulated the effects of lifestyle
intervention in the DPS participants. FH
did not affect the result of lifestyle in-
tervention during the entire follow-up.
We did not observe any aggregation of
known genetic risk variants in persons
with FH+, nor did genetic risk variants
modify the incidence of diabetes. On the
basis of different analyses, in addition to
the intervention, fasting and 2-h plasma
glucose and fasting insulin at baseline,
and the 1-year changes of 2-h plasma
glucose and 2-h insulin were the main
determinantsofthedevelopmentofdiabetes
Table 1—Baseline characteristics, diet, and physical activity of the DPS participants by
family history of type 2 diabetes
FH+ FH2 P value
N, men/women 327, 95/231 195, 76/119
Age, years 55 (7) 56 (7) 0.012
Men, BMI kg/m
2 30.1 (3.8) 29.6 (3.3) 0.365
Women, BMI kg/m
2 32.1 (5.0) 31.4 (4.3) 0.185
Fasting glucose, mmol/L 6.1 (0.7) 6.2 (0.8) 0.737
2-h glucose, mmol/L 8.9 (1.4) 8.9 (1.6) 0.897
Fasting insulin, mU/L 15 (7) 14 (8) 0.381
2-h insulin, mU/L 96 (60) 94 (73) 0.282
HOMA-IR 4.2 (2.3) 4.0 (2.3) 0.250
HOMA-B 120 (67) 115 (67) 0.217
Drug treatment for hypertension, % 28.8 30.4 0.692
CVD at baseline 7.9 8.6 0.866
Energy intake, kcal/day 1,788 (529) 1,705 (511) 0.079
Fat, E% 36.6 (6.6) 36.4 (6.6) 0.724
Saturated fats, E% 16.6 (4.2) 16.5 (4.2) 0.784
Carbohydrates, E% 43.5 (6.9) 43.2 (7.4) 0.664
Protein, E% 17.5 (3.5) 17.8 (3.3) 0.364
Dietary ﬁber, g/1,000 kcal 11.6 (3.7) 11.9 (4.4) 0.305
Total LTPA, h/week 6.6 (5.6) 8.1 (6.5) 0.007
Moderate-vigorous LTPA, h/week 2.6 (3.0) 2.9 (3.2) 0.279
Means(SD)areshownforcontinuousvariables.BoldfacedataindicatethesigniﬁcanceofPvalue(P,0.05or
less). CVD, cardiovascular disease; LTPA, leisure time physical activity.
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The Finnish Diabetes Prevention Studyduring the follow-up, independently of
the effects of genetic risk variants and
FH.
Although the participants with FH+
seemed to have a lower incidence of
diabetes than those with FH2 during
the ﬁrst 4 years of follow-up when the
active intervention was carried out, this
early difference disappeared during the
entire follow-up. The seemingly better
early response could be explained by the
fact that individuals with FH+ may be
more aware of the risk of diabetes than
others (21) and thus more motivated, as
suggestedbytheirgreaterdecreaseintotal
caloric intake during the ﬁrst year of in-
tervention (P = 0.012). In addition, the
mean 1-year change in the 2-h plasma
glucosevalueswasgreateramongthepar-
ticipants with FH+ in the lifestyle inter-
ventiongroup.Itshouldbenoticedthatat
baseline no differences were found in any
clinical or biochemical measurements,
which could explain the present ﬁndings
of the differences during the intervention
phase in the incidence of diabetes be-
tween individuals with FH+ and FH2.
The known genetic risk variants were
not associated with the FH of diabetes.
However, this may not be an unexpected
ﬁnding because it is known that risk loci
confer only 10% of the risk of type 2
diabetes (2,22). Furthermore, all partici-
pants in the DPS had screened IGT based
on two OGTTs and .60% had an FH+,
which also might indicate an aggregation
of genetic risk variants. In the general
population, FH+ varies from 25% to
40% depending on selection of popula-
tions in different studies (4,12–14). It
could be argued that a small sample size
could explain why no signiﬁcant associa-
tion between genetic risk variants and FH
or the type 2 diabetes risk was found.
However, this may not be the case, be-
cause in regression analyses not even a
trend to an association with the diabetes
risk was found. It is of note that the total
number of diabetes cases was 185 during
the entire follow-up. This ﬁgure is almost
comparableto255casesintheFramingham
Offspring Study (5), including 2,377 par-
ticipants with 28 years of follow-up. In
that study, the adjusted C-statistic was
0.595 without the genotype score and
0.615 with the score (P = 0.11). In a larger
studyonSwedishandFinnishcohorts,in-
cluding 18,831 individuals (4), of whom
2,201developeddiabetesduringamedian
follow-up of 23.5 years, the addition of
speciﬁcgenetic informationtoclinicalfac-
tors slightly improved the prediction of
Figure 1—Incidence of type 2 diabetes during the intervention period of 4 years (A) (end in-
dicated by a vertical line) and during the entire follow-up period (B) by FH and randomization
group (intervention vs. control) in the DPS. Solid line is for the control group. During the in-
tervention follow-up of 4 years on average, intervention had signiﬁcant effect on the incidence of
type2diabetesintheFH+group(P=0.0002,*P=0.0008)butnotintheFH-group(P=0.61,*P=
0.11).Duringtheentirefollow-up,interventionhadaneffectinbothFH+(P=0.0004,*P=0.002)
andFH2(P=0.13,*P=0.006)groups.PisfromKaplan–Meieranalysis,*Pafteradjustmentfor
age, sex, baseline BMI, baseline fasting glucose, and study center in Cox regression model.
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Uusitupa and Associatesfuture diabetes, from 0.74 to 0.75 (the
area under the receiver operating char-
acteristic curve); however, the P value
was signiﬁcant (P =1 . 03 10
24). These
results are in line with the Health Pro-
fessionals Follow-up Study and Nurses’
HealthStudy(6)applyingacase-control
study design, inwhichGRS based on 10
polymorphisms in nine loci increased
the predictive value from 0.78 to 0.79
(P , 0.001). In the latter study, how-
ever, glucose values were not included
in the analyses (6). In both the DPP and
DPS, in which gene–lifestyle interac-
tions have been examined, lifestyle
changes abolished the increased risk of
type 2 diabetes in the carriers of the risk
allele at TCF7L2 locus (9,10). No other
studies have used a similar approach.
Thus, lifestyle intervention per se, at
leastinpart,seemstoabolishthegenetic
risk associations observed in observa-
tional cross-sectional and longitudinal
studies.
The main predictors of the incidence
of type 2 diabetes in our study were the
lifestyle intervention, fasting and 2-h glu-
cose, fasting insulin at baseline, and
1-year change in 2-h glucose and 2-h
insulin. The ﬁnding that the 1-year
changes in the 2-h glucose and insulin
levels were powerful predictors of diabe-
tes, whereas the 1-year change in fasting
glucose level, which primarily reﬂects
insulin secretion, did not contribute to
the success rate of prevention, suggests a
signiﬁcant role of an improvement of
insulin sensitivity along with weight re-
duction. Indeed, in a substudy of DPS,
there was a marked improvement of in-
s u l i ns e n s i t i v i t yb a s e do ni n t r a v e n o u s
glucose tolerance test along with weight
loss,butonlysmallchangeswerefoundin
insulin secretion (23). Overall, these re-
sults showthat anelevation offasting glu-
cose with poor insulin secretion capacity
and the degree of insulin resistance and
obesityremainthemainpredictivefactors
among known risk factors for type 2 di-
abetes. We cannot exclude the possibility
thattheknowngeneticriskvariantscould
have been operative in an earlier phase of
development of diabetes, but along with
this line, the changes in lifestyle also
might be more effective in earlier phases
of this disease.
Because insulin secretion and insulin
sensitivity are not independent of each
other, both mechanisms could be opera-
tive when searching biological explana-
tions for the markedly decreased risk of
diabetes in prevention trials such as the
DPS. It has been hypothesized that life-
style intervention may have beneﬁcial
effects on insulin secretion avoiding the
exhaustion of b-cells and thus delaying
the progression of disturbed insulin se-
cretion capacity. Because the decrease in
the 2-h glucose and insulin had a marked
impact on the risk reduction of diabetes,
webelievethatanimprovementininsulin
sensitivity and perhaps concomitant re-
covery of b-cell sensitivity to glucose
(24) could mainly explain the observed
beneﬁcial effects of changing lifestyles
on the diabetes risk.
To conclude, conventional risk fac-
tors and lifestyle changes known to de-
crease the risk of diabetes are the most
important predictors of type 2 diabetes in
persons with IGT, and lifestyle changes
overcome the impact of the known ge-
neticandfamilialrisk.Thisinformationis
important both for health professionals
andforpersonsatincreasedriskfortype2
diabetes. Our results in conjunction with
some former population-based studies
and the DPP genetic studies indicate that
genetic risk testing at this point may not
offer much additional information appli-
cable to prevention strategies of type 2
diabetes to that obtained from patients’
FH and the well-known clinical risk
markers.
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Fasting glucose (baseline) 1.93 (1.57–2.38) 3.5 3 10
210
D Fasting glucose (1-year change) 1.15 (0.96–1.38) 0.129
2-h glucose (baseline) 1.69 (1.39–2.05) 9.1 3 10
28
D 2-h glucose (1-year change) 1.62 (1.32–1.98) 3.4 3 10
26
Fasting insulin (baseline) 1.35 (1.06–1.73) 0.015
D Fasting insulin (1-year change) 1.18 (0.97–1.44) 0.103
2-h insulin (baseline) 1.05 (0.79–1.39) 0.755
D 2-h insulin (1-year change) 1.36 (1.05–1.75) 0.018
BMI (baseline) 1.18 (0.99–1.40) 0.061
D BMI (1-year change) 1.19 (0.98–1.44) 0.084
For dichotomous variables,HRsare shown forthe intervention group, FH+of T2DM, and male subjects. For
continuous variables, HRs are expressed as unit change per 1 SD. A, B, C represent alternative models: A =
effectsofFH,GRS, andinterventionwithoutclinicalvariables.B=includingclinicalvariables atbaseline.C=
including1-yearchangesinthesevariables(Coxregression,allmodelsareadjustedforage,sex,baselineBMI,
andstudycenter).BoldfacedataindicatethesigniﬁcanceofPvalue(P,0.005orless).T2DM,type2diabetes
mellitus.
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